CardioNet (NASDAQ:BEAT), which provides cardiac monitoring, manufacturing, and lab services, has just announced what may prove to be a significant catalyst in the company's development. BEAT with an $82 market cap, operates in the specialty health services industry. People with heart conditions known as arrhythmias need to wear a monitor which translates via information to physicians via wireless sensors any irregularities that would require attention and possibly emergency services. CardioNet has been at the same thing since 2002 when it received FDA approval for its core technology. The company has grown from 3000 initial adopters to over 500,000 users today on a national scale.
While BEAT did receive a national reimbursement code in 2010, which was obviously crucial...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|